Abstract
Immunogenic cell death (ICD) is a way of reengaging the tumor-specific immune system. ICD can be induced by treatment with chemotherapeutics. However, only a limited number of drugs and other treatment modalities have been shown to elicit the biomarker responses characteristic of ICD and to provide an anticancer benefit in vivo. Here, we report a rationally designed redox-active Au(I) bis-N-heterocyclic carbene that induces ICD both in vitro and in vivo. This work benefits from a synthetic pathway that allows for the facile preparation of asymmetric redox-active Au(I) bis-N-heterocyclic carbenes.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Agents / therapeutic use
-
Cell Line, Tumor
-
Coordination Complexes / chemistry*
-
Coordination Complexes / pharmacology
-
Coordination Complexes / therapeutic use
-
Endoplasmic Reticulum Stress / drug effects
-
Gold / chemistry*
-
Heterocyclic Compounds / chemistry
-
Humans
-
Immunogenic Cell Death / drug effects*
-
Methane / analogs & derivatives*
-
Methane / chemistry
-
Mice
-
Neoplasms / drug therapy
-
Neoplasms / pathology
-
Oxidation-Reduction
-
Reactive Oxygen Species / metabolism
-
Transplantation, Heterologous
Substances
-
Antineoplastic Agents
-
Coordination Complexes
-
Heterocyclic Compounds
-
Reactive Oxygen Species
-
carbene
-
Gold
-
Methane